An Update on Thrombotic Thrombocytopenia Syndrome Induced by a COVID-19 Vaccine from an Indian Perspective

Based The Oxford-Astra's Covid vaccine is sold as CovishieldTM in India, which is manufactured and
marketed by the Serum Institute of India. In India, 175 crore doses of the same vaccine produced by
the Pune-based Serum Institute, have been given out in India. The parent company has recently
made a startling disclosure about probable serious adverse effect of the vaccine that it can cause
thrombosis with thrombocytopenia syndrome (TTS). Naturally, this opens a Pandora’s Box about
the safety and adversity of the injection that each of us received. In few cases some adverse effects
have been reported including few recorded deaths. Social media users are debating the vaccine's
safety in response to this admission. While worries are legitimate, it's important to separate facts
from myths. Vaccines can cause some common side effects and, in some instances, very rare
serious side effects but the benefits always outweigh the risks. India could beat the pandemic due to
timely administration of the vaccine.